Stifel Downgrades Apogee Therapeutics to Hold, Sets $135 Target
Stifel downgraded Apogee Therapeutics to a hold rating with a $135 price target, a 1.85% upside from the current price.
Key Points
- Stifel downgraded Apogee Therapeutics to a hold rating with a price target of $135 on June 24, 2026.
- Stifel's $135 price target implies 1.85% upside from Apogee Therapeutics, Inc.'s ($APGE) current $132.55 share price.
- Apogee Therapeutics, trading at $132.88, has a market cap of $9.99 billion and a 52-week high of $133.0.
- Institutional investors like T. Rowe Price and FMR have adjusted their positions in Apogee Therapeutics.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Stifel downgraded Apogee Therapeutics, Inc. (NasdaqGM: APGE) to a hold rating, setting a price target of $135. Shares of Apogee traded near $132.88 on Wednesday.
Stifel vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Apogee Therapeutics
T. Rowe Price Investment Management, Inc. significantly increased its holdings in Apogee Therapeutics by 7,568,528 shares, ending with 10,300,984 shares valued at about $867.03 million. FMR LLC also boosted its stake by 1,037,253 shares, totaling 9,262,291 shares worth approximately $779.61 million. Meanwhile, Wellington Management Group LLP reduced its position by 370,882 shares, holding 4,375,703 shares valued at $368.30 million. BlackRock, Inc. added 301,657 shares to its holdings, now owning 4,085,651 shares valued at $343.89 million.
Apogee Therapeutics, Inc. Stock Down 1.8%
Shares of Apogee Therapeutics, Inc. traded near $132.88 on Wednesday. The company has a market capitalization of approximately $9.99 billion. With a forward P/E ratio of -25.52, Apogee isn't currently profitable. Its beta is 0.619, indicating lower volatility compared to the broader market. The stock's 52-week range is between $34.34 and $133.00, with a 50-day moving average of $84.76 and a 200-day moving average of $69.38. The company also maintains a strong liquidity position with a current ratio of 32.59 and a quick ratio of 32.39.
$APGE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Apogee Therapeutics reported no net margin and a return on equity of -28.47%. The company's EPS stands at -$4.33. Investors are looking forward to the next earnings release scheduled for August 10, 2026.
Insider Buying and Selling at Apogee Therapeutics, Inc.
On June 10, 2026, CEO Dr. Michael Thomas Henderson sold 20,000 shares at an average price of $83.38 under a pre-arranged Rule 10b5-1 trading plan. On June 9, 2026, several insiders, including Mark McKenna and William Jones Jr., each bought 7,657 shares without a specified purchase price.
Analysts Set New Price Targets
On June 24, 2026, Stifel downgraded Apogee Therapeutics to a hold rating with a $135 price target. Mizuho also downgraded the stock to hold on the same day, matching Stifel's target. On June 23, Deutsche Bank and Citigroup both downgraded Apogee to hold with a $135 target. The consensus among analysts is a strong buy, with a mean price target of $119.50 based on 16 analyst opinions.
About Apogee Therapeutics
Apogee Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing novel biologics to treat inflammatory and immunology conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease. The company, led by CEO Dr. Michael Thomas Henderson, employs 261 people. Apogee is advancing several therapies through clinical trials, including Zumilokibart (APG777) for atopic dermatitis and asthma.
Bottom Line
Stifel's downgrade of Apogee Therapeutics to hold reflects cautious sentiment among analysts, setting a target of $135. Apogee's stock, trading near its 52-week high, is closely watched by investors as it navigates clinical trials and market dynamics. Institutional activity shows varied interest, with major funds adjusting their positions. Remember, 13F filings and analyst ratings are backward-looking and may not reflect current conditions.
Get Apogee Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $APGE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.